Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
Definium Therapeutics will present positive topline Phase 3 data for DT120 ODT (lysergide) at the 2026 NEI Fall Congress, including the first congress presentation of the Panorama study in generalized anxiety disorder. Panorama is the company's second Phase 3 GAD study and the third positive Phase 3 readout for DT120, following positive results from Emerge in major depressive disorder and Voyage in GAD. Panorama enrolled 245 participants across roughly 32 sites; Voyage enrolled 214 and Emerge 149. A compilation of pooled Phase 3 safety data will also be presented.
Key figures
- Drug Name
- DT120 ODT (lysergide)
- Phase Of Trial
- Phase 3
- Emerge sites
- 20
- Voyage sites
- 35
- Panorama sites
- 32
- Emerge enrolled
- 149
- Voyage enrolled
- 214
- Panorama enrolled
- 245
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.